Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Urology |
| Online Access: | http://dx.doi.org/10.1155/2019/2479823 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554774925410304 |
|---|---|
| author | Jacob W. Bruinius Karl J. Dykema Sabrina L. Noyes Bin Tean Teh Brian R. Lane |
| author_facet | Jacob W. Bruinius Karl J. Dykema Sabrina L. Noyes Bin Tean Teh Brian R. Lane |
| author_sort | Jacob W. Bruinius |
| collection | DOAJ |
| description | There is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data supporting its use in ChRCC is much more limited. A 56-year-old underwent palliative nephrectomy for locally-advanced ChRCC with sarcomatoid differentiation. Tumor gene expression profiling using Affymetrix HG-U133 Plus 2.0 GeneChip platform demonstrated significantly elevated VEGF-C expression compared to normal renal tissue n=12 and other types RCC n=158. Adjuvant sunitinib was used to treat his residual unresectable retroperitoneal lymph nodes. He demonstrated an exceptional response and underwent complete surgical resection four months later. He has been managed with TKIs for nearly nine years with only minimal disease progression. Additional studies exploring treatment options for patients with non-clear cell RCC are needed; in their absence, we would recommend TKIs for patients whose tumors bear a similar molecular profile. |
| format | Article |
| id | doaj-art-15f854aaa8ee45babdcd8c8747d6cfae |
| institution | Kabale University |
| issn | 2090-696X 2090-6978 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Urology |
| spelling | doaj-art-15f854aaa8ee45babdcd8c8747d6cfae2025-02-03T05:50:34ZengWileyCase Reports in Urology2090-696X2090-69782019-01-01201910.1155/2019/24798232479823Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?Jacob W. Bruinius0Karl J. Dykema1Sabrina L. Noyes2Bin Tean Teh3Brian R. Lane4Spectrum Health, Grand Rapids, MI, USAVan Andel Research Institute, Grand Rapids, MI, USASpectrum Health, Grand Rapids, MI, USANational Cancer Centre Singapore, SingaporeSpectrum Health, Grand Rapids, MI, USAThere is sparse literature demonstrating effective treatments for metastatic chromophobe renal cell carcinoma (ChRCC). The tyrosine kinase inhibitor (TKI) sunitinib selectively inhibits the VEGF pathway and it is a standard care for metastatic clear cell renal cell carcinoma (ccRCC), although data supporting its use in ChRCC is much more limited. A 56-year-old underwent palliative nephrectomy for locally-advanced ChRCC with sarcomatoid differentiation. Tumor gene expression profiling using Affymetrix HG-U133 Plus 2.0 GeneChip platform demonstrated significantly elevated VEGF-C expression compared to normal renal tissue n=12 and other types RCC n=158. Adjuvant sunitinib was used to treat his residual unresectable retroperitoneal lymph nodes. He demonstrated an exceptional response and underwent complete surgical resection four months later. He has been managed with TKIs for nearly nine years with only minimal disease progression. Additional studies exploring treatment options for patients with non-clear cell RCC are needed; in their absence, we would recommend TKIs for patients whose tumors bear a similar molecular profile.http://dx.doi.org/10.1155/2019/2479823 |
| spellingShingle | Jacob W. Bruinius Karl J. Dykema Sabrina L. Noyes Bin Tean Teh Brian R. Lane Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? Case Reports in Urology |
| title | Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? |
| title_full | Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? |
| title_fullStr | Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? |
| title_full_unstemmed | Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? |
| title_short | Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment? |
| title_sort | exceptional response of metastatic chromophobe renal cell carcinoma to vascular endothelial growth factor vegf inhibitors should increased vegf c expression be used to guide treatment |
| url | http://dx.doi.org/10.1155/2019/2479823 |
| work_keys_str_mv | AT jacobwbruinius exceptionalresponseofmetastaticchromophoberenalcellcarcinomatovascularendothelialgrowthfactorvegfinhibitorsshouldincreasedvegfcexpressionbeusedtoguidetreatment AT karljdykema exceptionalresponseofmetastaticchromophoberenalcellcarcinomatovascularendothelialgrowthfactorvegfinhibitorsshouldincreasedvegfcexpressionbeusedtoguidetreatment AT sabrinalnoyes exceptionalresponseofmetastaticchromophoberenalcellcarcinomatovascularendothelialgrowthfactorvegfinhibitorsshouldincreasedvegfcexpressionbeusedtoguidetreatment AT binteanteh exceptionalresponseofmetastaticchromophoberenalcellcarcinomatovascularendothelialgrowthfactorvegfinhibitorsshouldincreasedvegfcexpressionbeusedtoguidetreatment AT brianrlane exceptionalresponseofmetastaticchromophoberenalcellcarcinomatovascularendothelialgrowthfactorvegfinhibitorsshouldincreasedvegfcexpressionbeusedtoguidetreatment |